0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Paraproteinemia-Associated Scleredema Treated Successfully With Intravenous Immunoglobulin FREE

A. Brooke Eastham, MD1,2,3; Alisa N. Femia, MD2,3; Nicole F. Velez, MD1,2,3; Hedy P. Smith, MD4; Ruth Ann Vleugels, MD, MPH2,3
[+] Author Affiliations
1Harvard Combined Dermatology Residency Program, Boston, Massachusetts
2Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
4Division of Hematology, Department of Medicine, Tufts Medical School, Boston, Massachusetts
JAMA Dermatol. 2014;150(7):788-789. doi:10.1001/jamadermatol.2013.8835.
Text Size: A A A
Published online

Scleredema is a fibromucinous connective tissue disease characterized by symmetric, nonpitting edema and induration of the face, neck, and trunk. Although the pathogenesis remains elusive, associations with infection, diabetes mellitus, and paraproteinemia have been established.1 Paraproteinemia-associated scleredema is typically characterized by a progressive course, for which no standard therapeutic protocol exists.2 To our knowledge, the patient described herein represents the first reported case of scleredema with paraproteinemia successfully treated with intravenous immunoglobulin (IVIG).

REPORT OF A CASE

A woman in her 40s presented with a 2-year history of progressive erythema and induration of the face, neck, and upper trunk. She denied a history of preceding infection or diabetes mellitus. Physical examination revealed erythema, brawny edema, and induration of the face, neck, upper trunk, and upper arms. There was significant limitation of neck flexion, extension, and lateral rotation as well as shoulder abduction and internal rotation (Figure, A). The patient denied difficulty swallowing or restricted breathing.

Place holder to copy figure label and caption
Figure.
Limited Range of Motion in a Woman With Scleredema

A, This image demonstrates marked restriction in shoulder abduction before intravenous immunoglobulin (IVIG) therapy. B, This image demonstrates significant improvement in shoulder abduction following IVIG therapy.

Graphic Jump Location

A skin biopsy from the upper back revealed dermal thickening with separation of enlarged collagen bundles by Alcian blue–positive mucin deposition, consistent with a diagnosis of scleredema. Findings from a complete metabolic panel, complete blood cell count, and assays for fasting glucose and glycosylated hemoglobin levels were within normal limits. Serum protein electrophoresis revealed an abnormal globulin peak. Immunofixation confirmed an IgA κ-band, and serum IgA level was elevated (933 mg/dL; normal range, 140-260 mg/dL). Investigation for multiple myeloma was negative, with normal findings on skeletal survey, bone marrow biopsy, and urine protein electrophoresis. A diagnosis of scleredema associated with IgA-κ paraproteinemia was established.

Initial treatment with thalidomide was unsuccessful. The patient then completed a 1-year regimen of weekly to bimonthly extracorporeal photophoresis (ECP) with initial success. However, therapeutic response to ECP plateaued, and eventually skin induration worsened and neck and shoulder range of motion (ROM) became more restricted. Interestingly, the patient subsequently reported improvement in symptoms after a flulike illness. For this reason, a 6-week course of pegylated-interferon was administered by her hematologist, but this resulted in no benefit.

Based on 2 recent publications demonstrating the efficacy of IVIG for scleredema associated with diabetes3 and streptococcal infection,4 monthly IVIG treatment was initiated at a dose of 2 g/kg over 2 consecutive days. After just 2 cycles, the patient noted significant improvement. After 5 cycles, her ROM continued to improve, as evident on clinical examination and careful evaluation of high-quality photographs of shoulder and neck ROM before and after IVIG therapy (Figure). Shoulder abduction improved from approximately 140 to 170 degrees over this time period. Serum IgA level after 6 monthly cycles of IVIG therapy remained elevated, though less than the initial measurement (841 mg/dL). At the patient’s most recent follow-up evaluation, the patient continued to receive monthly IVIG treatments with ongoing improvement in skin induration and stabilized ROM.

DISCUSSION

Although the efficacy of IVIG has been established in a variety of inflammatory diseases, its mechanism of action remains elusive. It may exert immunomodulatory and anti-inflammatory effects by suppression of proinflammatory cytokines, downregulation of adhesion molecules and chemokine receptors, and neutralization of superantigens.5

Treatment of scleredema, regardless of subtype, remains a challenge. Variable improvement has been reported with phototherapy, systemic corticosteroids, methotrexate, cyclosporine, ECP, and radiation.1 IVIG has had reported success in diabetes-associated and streptococcal-associated scleredema, in 1 case each. The rapid response to IVIG in this patient with IgA-κ paraproteinemia further supports the potential efficacy of IVIG treatment for scleredema. Despite marked clinical improvement, the patient’s IgA levels did not significantly decrease in concordant fashion with IVIG treatment. This finding suggests that the mechanism of action of IVIG resulting in therapeutic benefit in paraproteinemia-associated scleredema may be similar to that seen in scleredema associated with other causes rather than from directly lowering the paraprotein level. Additional investigation is necessary to further define the role of IVIG in the treatment of scleredema.

ARTICLE INFORMATION

Corresponding Author: Ruth Ann Vleugels, MD, MPH, Autoimmune Skin Disease Center, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115 (rvleugels@partners.org).

Published Online: May 21, 2014. doi:10.1001/jamadermatol.2013.8835.

Conflict of Interest Disclosures: None reported.

Funding/Support: Dr Vleugels’ career has been supported by a Medical Dermatology Career Development Award from the Dermatology Foundation.

Role of the Sponsor: The Dermatology Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Information: Dr Femia is now with the Department of Dermatology, New York University Medical Center, New York.

REFERENCES

Bowen  AR, Smith  L, Zone  JJ.  Scleredema adultorum of Buschke treated with radiation. Arch Dermatol. 2003;139(6):780-784.
PubMed   |  Link to Article
Stables  GI, Taylor  PC, Highet  AS.  Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol. 2000;142(4):781-783.
PubMed   |  Link to Article
Barde  C, Masouyé  I, Saurat  JH, Le Gal  FA.  Scleroedema adultorum Buschke in a diabetic subject: intravenous immunoglobulin therapy [in French]. Ann Dermatol Venereol. 2009;136(4):360-363.
PubMed   |  Link to Article
Aichelburg  MC, Loewe  R, Schicher  N,  et al.  Successful treatment of poststreptococcal scleredema adultorum Buschke with intravenous immunoglobulins. Arch Dermatol. 2012;148(10):1126-1128.
PubMed   |  Link to Article
Gelfand  EW.  Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015-2025.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure.
Limited Range of Motion in a Woman With Scleredema

A, This image demonstrates marked restriction in shoulder abduction before intravenous immunoglobulin (IVIG) therapy. B, This image demonstrates significant improvement in shoulder abduction following IVIG therapy.

Graphic Jump Location

Tables

References

Bowen  AR, Smith  L, Zone  JJ.  Scleredema adultorum of Buschke treated with radiation. Arch Dermatol. 2003;139(6):780-784.
PubMed   |  Link to Article
Stables  GI, Taylor  PC, Highet  AS.  Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol. 2000;142(4):781-783.
PubMed   |  Link to Article
Barde  C, Masouyé  I, Saurat  JH, Le Gal  FA.  Scleroedema adultorum Buschke in a diabetic subject: intravenous immunoglobulin therapy [in French]. Ann Dermatol Venereol. 2009;136(4):360-363.
PubMed   |  Link to Article
Aichelburg  MC, Loewe  R, Schicher  N,  et al.  Successful treatment of poststreptococcal scleredema adultorum Buschke with intravenous immunoglobulins. Arch Dermatol. 2012;148(10):1126-1128.
PubMed   |  Link to Article
Gelfand  EW.  Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015-2025.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

450 Views
0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
×